收藏切换
Safety of Small Molecule Anti-SARS-CoV-2 Drugs During Pregnancy and Lactation
收藏切换
PDF
Qian SHEN1, Jinqi ZHENG1, Shuixian ZHANG2, Mengru BAI2, *
Chinese Pharmaceutical Journal | 2024, 59(18) : 1757 - 1763
Less
收藏切换
Chinese Pharmaceutical Journal | 2024, 59(18): 1757-1763
Safety of Small Molecule Anti-SARS-CoV-2 Drugs During Pregnancy and Lactation
Full
Qian SHEN1, Jinqi ZHENG1, Shuixian ZHANG2, Mengru BAI2, *
Affiliations
  • 1 Zhejiang Research Center for API Security, Zhejiang Institute for Food and Drug Control, Hangzhou 310052, China
  • 2 Hangzhou First People's Hospital, Hangzhou 310006, China
Published: 2024-09-22 doi: 10.11669/cpj.2024.18.012
Outline
收藏切换

OBJECTIVE Pregnant women are at a high risk of severe/critical SARS-CoV-2 infection, which can cause serious harm to both mothers and fetuses. Therefore, safe and effective medications are urgently needed. The current circulating strain Omicron variant JN.1 has been observed to elicit immune escape, leading to a decline in the efficacy of vaccines and neutralizing antibody drugs. As a result, the importance of small molecule antiviral drugs has become increasingly apparent, but their safety in pregnant and lactating women are not clear. METHODS Through searching domestic and international literature and databases, this paper reviews the safety data and experience of the approved small molecule anti-SARS-CoV-2 drugs (including remdesivir, molnupiravir, azvudine, renmindevir, nirmatrelvir/ritonavir, simnotrelvir/ritonavir, and leritrelvir) during pregnancy and lactation. The paper also presents information on genetic toxicity, animal and human reproductive toxicity, placental transport, and milk secretion. RESULTS Among them, the research data on remdesivir and nirmatrelvir/ritonavir are relatively sufficient. Animal studies have not found obvious reproductive toxicity, and the use of these drugs during human pregnancy has not shown serious adverse effects on mothers and fetuses. However, remdesivir is not yet listed in our country. CONCLUSION Nirmatrelvir/ritonavir may be an option for anti-SARS-CoV-2 treatment during pregnancy, and breast-feeding should be done after the drug is cleared.

nirmatrelvir/ritonavir  /  remdesivir  /  SARS-CoV-2  /  pregnancy  /  lactation
Qian SHEN, Jinqi ZHENG, Shuixian ZHANG, Mengru BAI. Safety of Small Molecule Anti-SARS-CoV-2 Drugs During Pregnancy and Lactation[J]. Chinese Pharmaceutical Journal, 2024 , 59 (18) : 1757 -1763 . DOI: 10.11669/cpj.2024.18.012
Year 2024 volume 59 Issue 18
PDF
128
63
Cite this Article
BibTeX
Article Info
doi: 10.11669/cpj.2024.18.012
  • Receive Date:2023-10-13
  • Online Date:2025-12-30
  • Published:2024-09-22
Article Data
Affiliations
History
  • Received:2023-10-13
Funding
Affiliations
    1 Zhejiang Research Center for API Security, Zhejiang Institute for Food and Drug Control, Hangzhou 310052, China
    2 Hangzhou First People's Hospital, Hangzhou 310006, China
References
Share
https://castjournals.cast.org.cn/joweb/zgyxzz/EN/10.11669/cpj.2024.18.012
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT